TrialThe Journal of dermatology2024

Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.

Yoji Hirai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.